Clinical Trial Update: Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for anlotinib combined with chemotherapy as first-line treatment in advanced NSCLC (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: NSCLC, Adenocarcinoma | Phase 1, Phase 2 | Status: UNKNOWN